

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

---

**CURRENT REPORT**

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 8, 2021

**Olema Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

---

Delaware  
(State or other jurisdiction  
of incorporation)

001-39712  
(Commission  
File Number)

30-0409740  
(I.R.S. Employer  
Identification No.)

512 2nd Street, 4th Floor  
San Francisco, California  
(Address of principal executive offices)

94107  
(Zip Code)

(415) 651-3316

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 par value per share	OLMA	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 8, 2021, Olema Pharmaceuticals, Inc. (the "Company") virtually held its 2021 annual meeting of stockholders (the "Annual Meeting"). Present at the Annual Meeting virtually or by proxy were the holders of 29,279,542 shares of common stock of the Company, representing 72.9% of the 40,169,738 shares of common stock outstanding as of the close of business on April 21, 2021, the record date for the Annual Meeting, and constituting a quorum for the transaction of business.

At the Annual Meeting, the Company's stockholders voted on two proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 27, 2021. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for or against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter.

*Proposal 1.* Stockholders elected each of the three nominees for Class I director to serve until the Company's 2024 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified. The votes regarding the election of directors were as follows:

<b>Director Name</b>	<b>Votes For</b>	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
Ian Clark	25,587,525	2,915,583	776,434
Sandra Horning, M.D.	28,476,444	26,664	776,434
Gorjan Hrustanovic, Ph.D.	25,690,868	2,812,240	776,434

*Proposal 2.* Stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. The voting results were as follows:

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>
29,279,502	22	18

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OLEMA PHARMACEUTICALS, INC**

Dated: June 9, 2021

By: /s/ John B. Moriarty, Jr.

John B. Moriarty, Jr.  
Executive Vice President, Chief Legal Officer and  
Corporate Secretary

---